# Alpha Tau Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alpha-tau-medical

- Industry: Medical Devices & Equipment
- Headquarters: Jerusalem, Israel
- Website: www.alphataumedical.com
- Total disclosed funding: $26M
- Latest round: Series B (Jun 4, 2020)
- Investors on record: 3

## About

Alpha Tau Medical, Ltd. is an innovative healthcare company focused on developing advanced cancer treatment technologies utilizing its proprietary Alpha DaRT technology, aimed at enhancing patient outcomes through localized cancer therapy.Alpha Tau Medical, Ltd. is established in 2016 in Jerusalem, Israel, specializing in cancer treatment via its unique Alpha DaRT technology. The firm has undergone no significant pivots or changes in its business strategy since its inception. Uzi Sofer is the current CEO, and the company has participated in 4 deals, with the most recent deal occurring on July 8, 2021. In this round, the firm raised USD 92 mn through PIPE funding from investors including Grand Decade, Medison Ventures, OurCrowd, Regah Ventures, and Yozma Group Korea, bringing the total amount raised to USD 92 mn.Alpha Tau Medical offers cutting-edge cancer treatment solutions, primarily focusing on its Alpha DaRT technology, which provides localized treatment to minimize side effects while maximizing efficacy. The technology is designed to target cancer cells directly, enhancing patient care. This firm caters to healthcare providers and institutions involved in cancer treatment, aiming to improve outcomes for patients across various cancer types.The revenue model for Alpha Tau Medical is centered around its proprietary treatment technology, generating income primarily through partnerships with healthcare facilities that utilize its Alpha DaRT technology for cancer treatment. The firm is structured to support predictable revenue generation in the healthcare sector, driven by the adoption of its advanced treatment solutions.With the recent investment of USD 92 mn received on July 8, 2021, Alpha Tau Medical plans to further develop its treatment pipelines to expand its therapeutic offerings. The company is targeting growth in North America and Europe, aiming to enhance its market presence by 2023. The funding will be strategically utilized to bolster research and development efforts, ensuring the successful rollout of new treatments in these key markets.

## Funding rounds

- Series B, Jun 4, 2020, $26M — Shavit Capital, OurCrowd, Medison Ventures

## Investors

- Shavit Capital (https://capitalatlas.ai/funds/shavit-capital) — Series B
- OurCrowd (https://capitalatlas.ai/funds/ourcrowd) — Series B
- Medison Ventures (https://capitalatlas.ai/funds/medison-ventures) — Series B